INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $879,279 | -17.7% | 16,880 | 0.0% | 0.03% | -21.6% |
| Q2 2023 | $1,068,842 | +27.5% | 16,880 | +9.0% | 0.04% | +23.3% |
| Q1 2023 | $838,242 | -47.3% | 15,480 | -48.5% | 0.03% | -50.8% |
| Q4 2022 | $1,591,834 | +6.3% | 30,080 | -6.5% | 0.06% | -1.6% |
| Q3 2022 | $1,497,000 | -18.5% | 32,180 | 0.0% | 0.06% | -13.9% |
| Q2 2022 | $1,837,000 | -6.7% | 32,180 | 0.0% | 0.07% | +9.1% |
| Q1 2022 | $1,969,000 | +16.9% | 32,180 | 0.0% | 0.07% | +22.2% |
| Q4 2021 | $1,684,000 | -71.4% | 32,180 | -79.7% | 0.05% | -73.3% |
| Q3 2021 | $5,897,000 | -15.9% | 158,180 | -7.9% | 0.20% | -16.5% |
| Q2 2021 | $7,009,000 | +20.3% | 171,700 | 0.0% | 0.24% | +12.0% |
| Q1 2021 | $5,826,000 | -20.8% | 171,700 | -25.8% | 0.22% | -35.5% |
| Q4 2020 | $7,355,000 | +117.2% | 231,300 | +75.2% | 0.34% | +91.4% |
| Q3 2020 | $3,387,000 | -6.4% | 132,000 | -6.4% | 0.18% | -13.4% |
| Q2 2020 | $3,619,000 | – | 141,000 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |